Aspire Biopharma shares surge 21.81% intraday after subsidiary secures TruLife distribution deal to expand BUZZ BOMB™ retail footprint.

Aspire Biopharma surged 21.81% intraday following the announcement that its subsidiary, Buzz Bomb Caffeine Company, signed a distribution agreement with TruLife Distribution to expand the retail footprint of BUZZ BOMB™ caffeine products. The partnership targets natural, organic, specialty, and mass-merchandiser channels, leveraging TruLife’s expertise to scale the innovative dry-powder caffeine stick, which offers a convenient, water-free energy solution. Executives from both companies highlighted the strategic value of the deal, emphasizing BUZZ BOMB’s differentiation in the on-the-go energy market and the potential for significant retail expansion. The agreement, announced on March 19, 2026, aligns with the stock’s sharp intraday gain, reflecting investor optimism about the brand’s growth prospects and market penetration.